Nasus Pharma CEO Issues 2025 Letter to Shareholders - Nasus Pharma (AMEX:NSRX)

Core Insights - 2025 has been a transformational year for Nasus Pharma, focusing on developing innovative intranasal products for emergency medical conditions [2] - The company has made significant progress with its proprietary Nasax powder technology, which enhances intranasal drug absorption [2][8] Clinical Development - Nasus Pharma presented positive data from early clinical trials of NS002, an intranasal epinephrine powder formulation, showing faster and higher absorption compared to traditional injectables [3] - The company received authorization from Health Canada to initiate a Phase 2 clinical study of NS002, with the first patient dosed in an open-label trial [6] - An interim analysis of the Phase 2 study is expected to be reported in early Q1 2026 [6][10] Financial Position - The company successfully completed its initial public offering in August 2025, raising $10 million in gross proceeds, which strengthened its financial position [4] Collaborations and Partnerships - In October 2025, Nasus Pharma expanded collaboration agreements with Aptar France S.A.S. and AptarGroup Inc. to support the clinical development and commercialization of NS002 [5] Future Plans - The company aims to initiate first-in-human studies for one or two additional pipeline products in 2026 while continuing to advance NS002 [7] - Key regulatory and clinical milestones are planned for NS002, including an Investigational New Drug submission in Q3 2026 and pivotal study initiation in Q3 2026 [10]